TGFBR2 and neoplasm: USP8 increases TβRII+ circulating extracellular vesicles, thus inducing T cell exhaustion and chemoimmunotherapy resistance.[51] USP8 inhibitor combination with PD‐1/PD‐L1 immunotherapy may be a promising approach to enhance anti‐tumor efficacy.